FDA approves Lilly diabetes drug that helps patients lose weight
The drug has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster, with potential annual sales in the billions of dollars.Read More
Lilly CEO has leaders talking about whether state is doing enough to grow Indiana
David Ricks’ lunchtime speech to The Economic Club of Indiana—repeated on social media by those in attendance and reported by IBJ and local TV stations—has reverberated across the state.Read More
Lilly says experimental drug helped patients lose up to 22% of body weight
The drug, called tirzepatide, has been closely watched by medical professionals and is viewed by financial analysts as possible blockbuster, with potential annual sales in the billions of dollars.Read More
Lilly shareholders to vote again on splitting CEO, board chair roles
For the third year in a row, an investor is proposing that the pharmaceutical company scrap the tradition of combining the role of chief executive officer and board chair.Read More
When it comes to competing for jobs, Indiana is far behind the curve in critical ways, Eli Lilly and Co. CEO David Ricks told a lunch crowd Wednesday at the Economic Club of Indiana.
Since early March, the Lilly Endowment has sold 1.3 million shares of Eli Lilly and Co. stock, raising $391 million, according to government filings.
The Affordable Insulin Now Act will serve as a political vehicle to rally Democrats and force Republicans who oppose it into uncomfortable votes ahead of the midterms.
The Indianapolis-based pharmaceutical company said the facility is part of its strategy to advance RNA-based therapeutics and builds on its acquisition of Prevail Therapeutics, a gene therapy company based in New York.
The Indianapolis-based drugmaker said the antibody is effective against the omicron variant and it has already manufactured several hundred thousand doses. The deal calls for the federal government to pay Lilly more than $720 million.
The deal calls for the federal government to pay Eli Lilly and Co. more than $720 million for the antibody, which the company said is effective against all COVID-19 variants.
Lisa Schlehuber has served as CEO of Indianapolis-based Elements Financial since 2005. She’ll retire from the role in April, the credit union announced Wednesday.
In December, the U.S. government paused distribution of Lilly’s two previous antibodies, saying they did not appear effective against the omicron variant.
Lilly said it selected Concord, North Carolina, because of the manufacturing technology experience of the local labor force; its proximity to universities with strong science, technology, engineering and math programs; and its access to major transportation infrastructure.
Indianapolis-based Eli Lilly and Co., one of three primary U.S. insulin manufacturers, said it was “deeply disappointed by the false accusations and inaccurate claims” made by the attorney general.
The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the COVID-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.
The federal government has resumed shipping all three monoclonal antibody treatments—including one made by Indianapolis-based Eli Lilly and Co.—that are authorized for early-stage COVID-19 to states despite evidence that two might be ineffective against the omicron variant.
Indianapolis-based Eli Lilly and Co. will make an initial $50 million payment to Entos Pharmaceuticals. Entos also could receive up to $400 million in potential milestone payments, as well as royalties, for successful products.
The pharmaceutical giant has quietly returned to making political contributions to 14 Republican lawmakers who voted against certifying the 2020 election results, according to a report issued Monday by watchdog group Accountable.US.
The U.S. Department of Health and Human Services cited new data that shows the therapies are unlikely to be effective against the Omicron variant.
Eli Lilly’s blockbuster drug for osteoporosis, Forteo, could face generic competition from Indian drugmaker Sun Pharmaceuticals if the company can get a federal judge to declare that a Lilly patent won’t be infringed.